PD-1阻断增强埃罗妥珠单抗在小鼠肿瘤模型中的疗效
本研究在体外及多发性骨髓瘤患者中观察埃罗妥珠单抗对自然杀伤(NK)细胞的作用,并在表达人SLAMF7的小鼠肿瘤模型中评估抗PD-1抗体与埃罗妥珠单抗-g2a联用的效果。结果显示埃罗妥珠单抗促进NK细胞活化,联合抗PD-1抗体可显著增强其抗肿瘤活性。
要点
- 埃罗妥珠单抗与人NK细胞及表达SLAMF7的骨髓瘤细胞共培养时促进NK细胞活化。
- 埃罗妥珠单抗治疗患者骨髓穿刺液中活化NK细胞频率增加。
- 小鼠模型中埃罗妥珠单抗-g2a最大抗肿瘤疗效需Fcγ受体阳性NK细胞和CD8+ T细胞,联合抗PD-1抗体显著增强。
核心结论
- 这些观察支持在骨髓瘤患者中开展埃罗妥珠单抗联合抗PD-1抗体治疗的临床研究。
研究设计与样本
- 体外研究、多发性骨髓瘤患者骨髓穿刺液分析及表达人SLAMF7的小鼠肿瘤模型研究。
主要发现
- 埃罗妥珠单抗加入人NK细胞与表达SLAMF7的骨髓瘤细胞共培养时促进NK细胞活化。
- 埃罗妥珠单抗治疗患者骨髓穿刺液中活化NK细胞频率增加。
- 在小鼠肿瘤模型中,埃罗妥珠单抗-g2a的最大抗肿瘤疗效需要Fcγ受体阳性NK细胞和CD8+ T细胞,联合抗PD-1抗体可显著增强。
- 小鼠模型中埃罗妥珠单抗-g2a与抗PD-1抗体联合治疗促进肿瘤浸润NK细胞和CD8+ T细胞活化,并增加肿瘤内细胞因子和趋化因子释放。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Elotuzumab, a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7) on myeloma cells, was developed to treat patients with multiple myeloma (MM). Elotuzumab has a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell-mediated antibody-dependent cellular cytotoxicity. This study aimed to characterize the effects of elotuzumab on NK cells in vitro and in patients with MM and to determine whether elotuzumab antitumor activity was improved by programmed death receptor-1 (PD-1) blockade. Elotuzumab promoted NK cell activation when added to a coculture of human NK cells and SLAMF7-expressing myeloma cells. An increased frequency of activated NK cells was observed in bone marrow aspirates from elotuzumab-treated patients. In mouse tumor models expressing hSLAMF7, maximal antitumor efficacy of a murine immunoglobulin G2a version of elotuzumab (elotuzumab-g2a) required both Fcγ receptor-expressing NK cells and CD8+ T cells and was significantly enhanced by coadministration of anti-PD-1 antibody. In these mouse models, elotuzumab-g2a and anti-PD-1 combination treatment promoted tumor-infiltrating NK and CD8+ T-cell activation, as well as increased intratumoral cytokine and chemokine release. These observations support the rationale for clinical investigation of elotuzumab/anti-PD-1 combination therapy in patients with MM.
引用
- Bezman NA, Jhatakia A, Kearney AY, et al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv. 2017. PMID: 29296719. doi:10.1182/bloodadvances.2017004382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。